2011 Speakers Included

Bill McLaury is Executive Director, Novartis Pharma Supply Chain for North America and has been with Novartis for over 25 years. He is responsible for the supply chain management process used by Novartis in the US and Canada and he leads the group with operational responsibility for production planning, physical distribution, warehousing, transportation, international trade and portfolio management.

Bill has a Bachelor’s degree in Supply Chain Management from Bowling Green State University and a Master’s Certificate in Project Management from George Washington University. Bill is also a Certified Production and Inventory Manager and he serves on the Board of Advisors for the Supply Chain Management Center at Rutgers University.

Ron Guido has 34 years experience in the health care industry with Johnson & Johnson.  He has held executive positions in the areas of engineering, operations, sales, product marketing, international marketing, new business development, information technology and general management. His current role is Vice President, Global Brand Protection and Supply Chain Integrity for Johnson & Johnson where his group is responsible for anti-counterfeiting programs and policies.

He is a Board member for a charitable medical organization known as Operation Smile, an advisor to the Rothman Institute of Entrepreneurial Studies at Farleigh Dickinson University, an instructor with the Rutgers University Strategic Health Care mini-MBATM program and holds three patents for medical devices.

David Buynak is the Program Leader for AstraZeneca’s Serialization Strategy Team within North America Operations. Mr. Buynak has over 25 years of experience in Operations including roles in Quality Assurance, Regulatory Affairs, Technical Services and Plant Management. Mr. Buynak has spent the past 5 years specializing in developing progressive strategies for AstraZeneca in product and supply chain security in North America.

AstraZeneca employs a multi-layered product security strategy that is focused on ensuring its patients receive authentic medicines from legitimate sources. Mr. Buynak is responsible for development of AstraZeneca’s serialization adoption plan and its implementation across multiple regional business units and global supply sites. Mr. Buynak has also lead AstraZeneca’s Drug Pedigree Strategy Team that supported the response to wholesale customers and supply chain management needs in Florida. From 2006-2008, AstraZeneca was active in piloting serialization technologies that supported electronic pedigree requirements at the line level and within warehouse operations. Since that time, Mr. Buynak has been involved with supply chain partners to track drug pedigrees laws in California and other states through active participation in PhRMA and GS1 Healthcare work groups. Mr. Buynak joined AstraZeneca in 2000 and holds a Bachelor of Arts in Biology from Gettysburg College.

Reid H. Graves currently works at Merck & Co., Inc. as the Senior Business Lead for Supply Chain Master Data. He designed the Material Master and manufacturing objects to enable an end-to-end view of products across the global enterprise. He is the primary architect for several custom-built web-based systems for managing Merck's global supply chains, worldwide sales, inventory, and production/quality cycle times. He directed the Inventory Management program ($1.8 billion) resulting in demonstrated supply chain improvements.

Reid has 33 years of service with broad experience in manufacturing and packaging operations for solid dosage forms and sterile antibiotics, Technical Services, Quality, Supply Chain, and IT systems development. Current responsibilities focused on the global deployment of Merck's ERP (SAP) solution. He has a Bachelor's and Master’s degree in Biology from the College of William and Mary in Virginia. In 2011, Reid joined the Advisory Board for 20/20 Pharma.

Bill Cherubino has been with Johnson and Johnson for over 13 years and is currently the Group Manager of Equity Protection for the Consumer Americas Procurement organization.  The Equity Protection group is responsible for identifying leading indicators of risk and remediating same via robust intervention processes across all Business Units in the Consumer portfolio, encompassing over 1300 suppliers and $1.5B in spend.  Bill has held various Operations roles in his Johnson and Johnson tenure including National Manager of Planning for the US Splenda launch, ERP integration project lead, strategic supplier management and cross-sector program management. 

Prior to joining J&J Bill spent 9 years as a General Manager and Controller of a manufacturer’s representative; 2 years as a securities trader; and 6 years as a private business owner.  Bill earned a BS in Communications from the University of Utah and securities licenses with First Investors Corp.

Anthony Flammia strives to optimize supply chain performance, and has done so for over twenty years in the pharmaceutical, medical device and consumer products industries. Mr. Flammia has an MBA from Fairleigh Dickinson University and a BS degree from Florida Institute of Technology. His operating experience includes strategic planning & network design, manufacturing operations, strategic sourcing strategy, information technology systems in a Part 11 compliance environment, project management, and global supply chain operations.

Mr. Flammia has also directed the global supply chain practice for a major consulting group in which he advised major blue chip companies on global manufacturing and supply chain strategies. Currently serving as a Senior Executive in the pharmaceutical industry for the last eight years, he has worked specifically on building a global outsourced manufacturing network & supply chain infrastructure. This is to support a small, but fast growing specialized pharmaceutical company, where sales have grown from $38 million to an excess of $450 million annually.

Mr. Flammia is responsible for the Global Network Strategy, Manufacturing Operations, Global Supply Compliance, Manufacturing Devolvement, Strategic Sourcing, Global Contracting & Pricing, and Global Supply Chain across the globe for both commercial & clinical supply. Before joining The Medicines Company, Mr. Flammia was with Bristol Myers Squibb serving in a multitude of capacities at both the plant & corporate levels. His main responsibility was Director of Manufacturing Supply Chain for the Americas Region, which included thirteen facilities in North America, Latin & Central America, and Puerto Rico.

Mr. Flammia served on both the Technical Operations group for Worldwide Medicines and the Medical Device business unit. Previously, he worked with Ernst & Young Global Supply Chain practice and Colgate Palmolive in the Oral Care business unit. Mr. Flammia is also a leader in his local community. He finished serving his second term as a member of the Board of Education for the Hunterdon Central Regional High School District in Flemington, NJ. The district includes one of the ten largest high schools in the state of New Jersey. He served as Chairman of the Curriculum & Technology committee overseeing the IT technology investment and insuring a competitive program of studies is offered to a diverse student body. Mr. Flammia also served on Building & Grounds overseeing a $30 million facility expansion and on the Human Resource committee overseeing a staff of over 500 employees. Having experience in both consulting and executive leadership in directly managing supply chains under a variety of challenging situations, Mr. Flammia offers a unique perspective on the industry’s opportunities for growth & profit optimization.

Carl is a veteran of FDA regulated operations, with 27 years of diversified global experience in both large and small pharmaceutical firms. Carl has made contributions in the areas of global drug commercialization, development, project management & supply chain management in “Big Pharma” and “Small Biotech”. Over the past three years, Carl prepared for commercialization and launched a novel schizophrenia drug for Dainippon Sumitomo Pharma America, which is now Sunovion Pharmaceuticals. Carl founded Global Pharma Consulting in 2004 to provide Rx commercialization services expertise to start-up pharmaceutical firms.

For four years, Carl prepared Kyowa Pharmaceuticals for commercialization of a novel therapy for Parkinsons Disease while running his own firm. Japanese companies have embraced Carl’s virtual model. From 1998 to 2001, Carl was a Corporate Officer and Vice President of Operations at Anesta Pharmaceutical in Salt Lake City with responsibilities for worldwide clinical & commercial manufacturing, tech transfer, validation, CMC filings and regulatory inspection & approval by UK MHRA and US FDA. Carl helped to successfully commercialize Actiq for cancer pain in the US, EU, and globally. Actiq reached $700 million in sales for treatment of breakthrough cancer pain.

Previously, in “Big Pharma”, Carl was Vice President, Worldwide Supply Chain Management, Bristol-Myers Squibb ConvaTec and Vice President, Materials Management, Hoffman-La Roche. His background also includes Director level positions at Pfizer Pharmaceuticals in new product planning, strategic planning and pharmaceutical systems. He began his career as a Merck Design Engineer. Mr. Accettura holds a BS degree in Mechanical Engineering from Cornell University (Class of ’75), an MS degree in Mechanical Engineering from the University of Illinois, and an MBA degree from New York University. He has served on the Advisory Board of the Cornell University Center for Manufacturing Enterprise. Carl has been a frequent speaker at the Cornell Engineering Enterprise Seminar, since 1990. Carl has been active professionally in PMA, ISPE, PDA, IVT, ASQ, and APICS.

Mahendra Pattni serves as a senior director of finance, Global Supply Chain at Shire Pharmaceuticals based in Wayne PA. He is responsible for providing operational and strategic leadership in supply chain finance. He is also working to deliver significant improvements and cost reductions in operations, and change management programs such as Lean Manufacturing.

Mahendra joined Shire in 2005 after working for 18 years at GlaxoSmithKline in various positions with increasing responsibilities. He started at GlaxoSmithKline in 1988 as a Cost Accountant at the Maidenhead plant in England and took various financial responsibilities at the plant before becoming the Plant Financial Controller in 1994. He was promoted to the Finance Director in charge of Supply Chain Capacity Planning at their West London headquarters.

Chuck Forsaith joined Purdue Pharma LP in 2001, after 21 years of service as both a New Hampshire municipal and State Police officer - and also having formally directed security operations for a United States military installation. With the New Hampshire State Police he served in supervisory capacities in both the uniform and detective divisions. He also acted as the Director of the New Hampshire Attorney General's Drug Enforcement Task Force. For the government, Chuck managed a physical security program which protected one of the military’s world-wide satellite tracking installations. His responsibilities with Purdue Pharma include managing all domestic and international supply chain security efforts, as well as regulatory compliance with all Federal supply chain security programs.

He also acts as the Chairman of the Pharmaceutical Cargo Security Coalition (PCSC), a group of over 400 individuals, from a variety of disciplines, who monitor the security of pharmaceutical goods in transit all over the world. He has lectured both domestically and internationally in the disciplines of Pharmaceutical Supply Chain and Site Security for such organizations as the Federal Bureau of Investigation, the US Food & Drug Administration, United States Customs, the Department of Homeland Security, the United States Merchant Marine Academy, ASIS, TAPA, the HDMA, NADDI, NACDS, Notre Dame College, the World Trade Group and the International Association of Biometrics.

He is an active member of the American Society of Industrial Security, the Transported Asset Protection Association, the Overseas Security Advisory Council, the National Association of Drug Diversion Investigators and the International Association of Chiefs of Police. He currently sits on the advisory council for the United States Merchant Marine Academy's ""Global Maritime Transportation School"" (GMATS) and is a former member of the Board of Director's for TAPA of the Americas.

Craig Malzahn, the Senior Director of Supply Chain at Human Genome Sciences, is responsible for supply strategy, production planning, logistics, manufacturing outsourcing, and manufacturing technical services. He has over 15 years of manufacturing and supply chain experience in biopharmaceuticals. Since 2005, he has led HGS’ Raxibacumab Core Team and delivery of anthrax anti-toxin doses to the Strategic National Stockpile and managed the relationship with the Biomedical Advanced Research and Development Authority.

Craig has led and served on various development, manufacturing, distribution and commercial joint governance teams with GlaxoSmithKline and Novartis. Prior to joining HGS, he directed pilot plant operations at Baxter BioSciences where he was responsible for clinical vaccine production. Craig performed in several roles at Baxter and North American Vaccine in facility start-up, technology transfer, fermentation and recovery disciplines.

Craig earned a M.S. degree in Biotechnology from Johns Hopkins University and a B.S. degree in Biology from Virginia Tech.

Bob’s early career started in the United States Navy, after graduating with merit from the U.S. Naval Academy in 1973. He served on active duty as a Naval Officer for over seven years, and earned several leadership and achievement awards before joining Westinghouse as a nuclear logistics engineer in 1980. In this role, Bob leveraged his Naval Academy training, Navy shipboard experience, and Navy Supply Corps training to effectively manage high-value critical inventories of prime components and equipment in support of the new construction and overhaul of the Navy’s nuclear power plants, in both surface ships and submarines.

Bob joined Merck & Co., Inc in 1982 as an Industrial Engineer, and held positions of increasing responsibility within the Operations area until 1988. Bob was then promoted to Manager, Strategic Planning for the company’s U.S. Human Health Division, where he led several Strategic Planning and Long Range Operating Planning cycles in support of the US business. In 1990 he became a Product Manager with responsibility for marketing planning activities for a variety of promoted products, as well as products under development.

Bob joined Astra Merck in January 1992 where, as a founding member of the original planning group and senior leadership team, he helped create the Company’s Vision and design and build the new organization. He served as Executive Director, Strategic Planning and Facilities Management until 1996, when he was appointed Sales Director of the Philadelphia Regional Business Unit in the Company’s sales organization. This move brought Bob’s broad background in marketing, planning and operations into the sales force, while simultaneously expanding his knowledge and experience in sales management. After exceeding all assigned sales goals as a Sales Director, Bob was promoted to Executive Sales Director, and was tasked with setting up a new regional sales office in Atlanta, GA. He subsequently led his southeast region team of over 200 sales people through a major reorganization of the sales force, followed by two back-to-back mergers with other companies.

Along the way, Bob consistently exceeded assigned sales goals for the region, and his region was ranked #2 out of 10 regions in the country. Bob’s leadership style, pragmatic management approach, and creativity and innovation in establishing new business processes won praise and approval by his sales peers and company executives. Many of Bob’s ideas were cited as “best practices” and adopted throughout the sales force company-wide. However, as a result of the second merger with Zeneca, Bob voluntarily left the company in September 1999 to pursue other career opportunities. Bob joined IMS Health Strategic Technologies in March 2000, and led a worldwide transition planning effort that resulted in the spin-off of Strategic Technologies and Clark-O’Neill from IMS Health. The two subsidiaries then joined to form a new publicly traded company called SYNAVANT. Bob was then promoted to Senior Vice President and General Manager for the Americas. He had responsibility for directing total operations and over 550 people who sell and deliver software technology products and services to the pharmaceutical industry. He was accountable for profit and loss associated with operations in the United States, Canada, and Latin America, with budget responsibilities of over $110 million in annual revenue and expenses of over $100 million.

As part of a corporate restructuring plan and buyout by a competitor, Bob took a severance package and left the company in September 2002. Bob engaged in consulting part-time as a Six-Sigma consultant with Uniworld Consulting while conducting a job search. He joined CIBA Vision in May 2003 in a newly created role as Vice President, Business Operations. In this role he was responsible for directing and managing a variety of regional business operations, including: customer service and call center operations, sales planning and analysis, lens care product planning, purchasing and logistics, commercialization program management, sales and operations planning (S&OP), process improvement initiatives (Six Sigma), and logistics/distribution operations.

Bob also managed Corporate Shared Services functions, including security, food service, facilities planning and management, and site operations for the worldwide headquarters campus. Despite the extreme variety of functional and project-related assignments, Bob consistently met or exceeded assigned goals every year, and earned several Quality Achievement and Leadership awards in this role. In 2009 Bob moved into a newly created role in Global Supply Chain where he is responsible for working within and across global supply chain to reduce end-to-end distribution costs for finished goods while delivering superior customer service. He established and led a global cross functional team that identified over 80 logistics projects/opportunities with potential annual savings exceeding $15 million (10%) of an annual spending base of $150 million. He delivered first-year (2009) savings of $9.2 million (+29% over $7.1 million target), and second-year savings of $16.0 million (+33% over $12.0 million target). Bob received the CEO 2010 Outstanding Achievement Award for Productivity in recognition of his successful efforts to reduce cost and improve capabilities, allowing the company to invest resources in growth initiatives and innovation. Bob also developed and implemented Perfect Order Index (POI) regionally and globally, which is now included as a KPI on the CIBA VISION executive team scorecard.

In summary, Bob Holmes has over 38 years of successful management and technical experience, with a broad business background obtained from extensive hands-on leadership in sales, marketing, strategic planning, human resources, administration, production, and logistics operations. His experience spans three industries, with a focus on life sciences/healthcare, and includes working at large multi-national companies as well as with start-up organizations.

Kevin has led the Planning & Logistics team at BioMarin since joining at the end of 2006, responsible for commercial and clinical products. BioMarin is a multinational biopharmaceutical company that specializes in providing first-to-market therapeutics to patients with rare genetic diseases. Kevin has over 20 years of experience in supply chain management focusing on sales & operations planning, demand management, inventory management, supply chain metrics, and systems development. Prior to BioMarin, Kevin worked for Johnson & Johnson in devices and diagnostics units and Honeywell Aerospace where he received a Six Sigma certification and extensive Lean Manufacturing training. He holds a BS with honors from Virginia Commonwealth University and graduate work from San Diego State University in Operations Management.

Security manager with 15+ years combined experience in public and private sectors. Broad experience to include law enforcement, fraud and conduct investigations, workplace violence mitigation, contract security management, senior level physical protection, meeting and event security, global risk assessment, international security program development, supply chain security and anti-counterfeiting technologies.

My background includes Security & Safety Management, Crisis Management/Communications, Asset Protection, Supply Chain Security, Executive Protection and Emergency Preparedness career in the Technology and Telecommunications industry, Health Care, and Pharmaceutical Industries. I have managed the development, implementation, and administration of programs that evaluate and respond to global threats; developed and implemented policies and procedures that protect corporations, their property and assets; developed and implemented physical, operational, investigative, and systems security countermeasures that protect the personnel, property, and assets of large corporations in both a centralized and decentralized environment.

I am recognized for my expertise in team leadership, consensus building, partner development, and relationship management. These skills have served as the foundation for meeting challenges, providing direction, committing people to action, and inspiring productivity and teamwork. I am a skilled negotiator who has consistently produced positive results within corporations. In each of my private sector experiences I have been successful in taking the organization to the next level.

Mike started his career with Novartis in 1984 as a process engineer at the then Ciba-Geigy facility in Summit NJ. Mike steadily progressed to senior Process engineer in the Chemical Development group, overseeing the manufacture of Drug Substance used in clinical testing.

Mike then went on to manage the Commercial Drug Substance operations at the Summit site. His next assignment was to direct all Commercial Manufacturing operations at the Summit site before the site was closed and operations moved to alternate Novartis facilities.

Mike then moved to the Suffern, NY site as head of Quality Management and Training where he laid the groundwork for the very successful LEAN manufacturing implementation at the plant. He was instrumental in training several hundred employees in the principle’s and practices of LEAN manufacturing.

In 2001Mike moved to the Supply Chain Management organization at the East Hanover, NJ site.

Mike’s current role at Novartis involves Project management for the Supply Chain area for all new Product launches, Production transfers, and Life cycle management changes for the Novartis US pharmaceutical business.

Mike has a BE degree in Chemical Engineering from Stevens Institute of Technology, and is a licensed professional engineer in the state of NJ. He lives locally in the East Hanover Area with his wife and son, and is very active in the local community volunteering his time for several charitable organizations.

Kristian Sibilitz, MSc in Engineering, has since 2009 been responsible for Logistics at Lundbeck, encompassing direct purchasing, contract manufacturing, artwork implementation, production planning, product costing, warehousing and distribution.

Prior to this, Kristian worked with planning, before taking responsibility for Lundbeck’s supply chain strategy and the management processes in the supply chain in his role as personal assistant to the Executive Vice President for Production. As head of Logistics, Kristian works with his organisation to strive for supply chain excellence from orchestrating suppliers to direct distribution and is constantly searching for innovative solutions to increase reliability and reduce cost.

Frank Binder is Director, International Logistics and Supply Chain, at Celgene, based in Switzerland. Currently his main task is expanding and managing Celgene’s international pharmaceutical logistics setup, optimizing the European distribution network while building a new distribution network across Asia. He is guided by his team’s mission statement “Products to the Patients – Every Time, On Time – Compliant & Cost-effective.”

Prior to this, Frank has worked in various Supply Chain roles at Hoffmann-La Roche, Novartis and at management consultancy Accenture. Thereby he’s gained a broad and deep Supply Chain Management expertise in the Pharmaceutical Industry, ranging from chemical production, biopharmaceutical manufacturing capacity planning, to logistics at a galenical manufacturing site, and finally to international logistics and distribution. Frank has been involved in many projects (mergers, divestments, ERP implementations, negotiations, product launches, entering new markets) and has very strong intercultural and language skills (fluent English, German, French, Spanish). He has international work experience (Switzerland, France, USA, Germany) and is frequently leading projects with partners across Asia, eg. in Singapore, Korea and other countries.

He has been speaker at industry conferences, e.g. at LogiPharma Asia 2009 and 2010 in Singapore, or at Pharma Resource and Capacity Management 2007, in Las Vegas. He has also been member of the advisory board of Logipharma Asia 2009 and 2010. A chemist by training (PhD in Physical Chemistry, University of Bern), Frank underwent post graduate business training at Cranfield School of Management and Harvard Business School.

Dr. Ravi Prakash Mathur is Director SCM – Head of Logistics with Dr. Reddy’s Laboratories Ltd. Based at Hyderabad, he is responsible for global logistics, distribution and central SCM for the organization. He was also a part of the spearhead team responsible of an organizational initiative based on ‘Theory of Constraints’. Dr. Mathur has 18 years of work experience in the field of International Logistics and Supply Chain Management. Prior to joining Dr. Reddy’s he worked as Manager – Logistics (Asia Pacific, Middle East and Africa) at DSM Anti Infectives India Ltd.

Dr. Mathur has also worked for more than ten years in the International Freight forwarding and Logistics industry. Working with reputed Multinational Corporations, he was instrumental in designing various International Logistics solutions for different partners across various verticals. In his stint with Panalpina World Transport (India), he worked as Head-Product and Pricing, Sea freight, South Asia.

Dr Mathur’s doctoral thesis was on the subject of supply chain systems for international freight. Recognitions include citation from ‘World Bank’ and International Finance Corporation for contribution to their publication ‘Doing Business in 2006’. His Biography has been profiled in various publications of Marquis Who’s Who.

Mr. Connell has over 25 years of experience in Manufacturing, Supply Chain and Operations Management in various industries. Prior to Iroko, he served as a Principal and Practice Director of Tunnell Consulting Inc., located in King of Prussia, Pennsylvania, where he joined in 1998. At Tunnell, he was responsible for developing products and accounts, recruiting consultants, managing ... projects at multiple client sites, managing project timelines and budgets, and delivering results on operations and supply chain engagements.

Mr. Connell held account responsibility for several Pharmaceutical clients including Novartis, Wyeth, Aventis, AmerisourceBergen and Mayne Pharma leading projects in areas such as Global Manufacturing and Supply Chain Strategy, QA/QC Process Improvement, Optimizing Global Distribution Networks, Developing Pharmaceutical Returns Process, Outsourcing Manufacturing and Distribution Operations, and Improving Sales and Operations Planning. He has been a speaker on Pharmaceutical Industry issues such as Managing Contract Manufacturers, Improving Quality Control Laboratories using Simulation Modeling and Outsourcing Transportation and Distribution at Pharmaceutical Industry events such as LogiPharma, The Conference for Capacity and Productivity Improvement in the Pharmaceutical Industry and for the Institute for Supply Management (ISM). Mr. Connell served as Member of the Council of Logistics Management (CLM) and the American Production & Inventory Control Society (APICS).

Professional Supply & Quality Leader with over 25 years of increasing responsibility in the Pharmaceutical & Chemical Process Industries. Global contributions within Manufacturing, Supply Chain and Technical / EPA Compliance / FDA Regulatory Affairs areas.

Michael holds a B.A. degree in Chemistry from Montclair State University and an M.B.A. in Operations Management from Drexel University.

Volker has been with Exel since 2005, and has been devoted to Life Sciences third party logistics since early 2000. Where account management is concerned, Volker currently manages Exel business with all Novartis and Pfizer business units in the Americas. He also leads the Sector's strategic planning and product development initiatives, including alliance partner relationships and direct distribution service products.

Volker came to Exel from Kuehne Nagel, where he last served as Vice President of Healthcare Business Development for North America. Prior to K+N, he spent most of his time product managing specialty businesses with early stage manufacturers in the healthcare industry.

He has both an MBA and a Masters in Mechanical Engineering from Rensselaer Polytechnic Institute. He earned his BS in Mechanical Engineering from the University of Virginia.

Les Sparrow has been with World Courier for 19 years. He is currently the Manager of Technical Support & Analytical Services for this specialty global transportation company that supports the bio/pharm industry in the rapid and secure transport of clinical supplies and diagnostic materials. Les leads a team that interfaces with every intra-company department, monitoring all cold chain related activity. In this role it is his responsibility to ensure that the company meets or exceeds client expectations by using optimum logistical planning and the most current tools to maintain temperature integrity. This group creates and modifies SOPs that secure this goal.

Over the course of Les’ tenure with the company he continues to interface with clients and employees in a training and/or consultant capacity in the areas of dangerous goods, cold chain, documentation and packaging. He has also been very involved in working with the airlines and cargo management.

Les participates in many trade shows and conferences relating to the pharmaceutical industry. He has been a featured cold chain speaker at various events including EPICS and IQPC.

Karen has supported the clinical study industry throughout her 15 year tenure at World Courier by preparing transportation recommendations for complex multinational pharmaceutical projects. Karen has worked with clinical research professionals to solve their most demanding protocol cold chain scenarios. She has focused on many U.S. biotechnology/pharmaceutical “hotbeds”, including Massachusetts, North Carolina, Colorado, Pennsylvania, and New York.

Subject matter expert for GE Healthcare’s Medical Diagnostics business regarding GS1 Global Standards, electronic coding, product serialization, and producttrack and trace (including electronic product pedigree). Coordinates intelligence gathering of global requirements, by market, for electronic coding, product serialization and traceability/authentication and then translates this information to formulate strategies for compliance solutions.While building compliance solutions for serialization and traceability/authentication, createsstrategiesfor building lean processes to achievereturn on investments.Leads the business’s efforts to build the necessary project models for execution.Core team leader for the business’s global design team for serialization and product authentication.